Pantoprazole Infusion Guidelines for Upper GI Bleeding

Initial Management

The American College of Gastroenterology recommends starting high-dose PPI therapy immediately upon presentation, even before endoscopy is performed, to reduce stigmata of recent bleeding and not delay urgent endoscopic intervention in patients with nonvariceal upper GI bleeding 1, 2
Administer the initial 80 mg IV bolus of pantoprazole as soon as upper GI bleeding is suspected in patients with high-risk endoscopic stigmata 1
Consider pre-endoscopy erythromycin to enhance gastric visualization during the procedure in patients with suspected upper GI bleeding 1

The American College of Gastroenterology recommends an 80 mg IV bolus followed immediately by 8 mg/hour continuous infusion for exactly 72 hours after successful endoscopic therapy in patients with high-risk endoscopic stigmata 1, 2
This high-dose continuous infusion regimen has demonstrated mortality benefit (OR 0.56, 95% CI 0.34-0.94) and reduced rebleeding rates (OR 0.43, 95% CI 0.29-0.63) in patients with nonvariceal upper GI bleeding 2
Transition to oral PPI 40 mg twice daily after completing the 72-hour infusion in patients with nonvariceal upper GI bleeding 1, 2
Continue oral PPI 40 mg once daily to allow complete mucosal healing in patients with nonvariceal upper GI bleeding 1, 2
Total duration of PPI therapy should be 6-8 weeks minimum to allow adequate mucosal healing in patients with nonvariceal upper GI bleeding 1, 2

The American College of Gastroenterology recommends this high-dose regimen specifically for patients with high-risk endoscopic stigmata, including active arterial bleeding, visible vessel, or adherent clot 1, 2
Patients with low-risk stigmata do not require this intensive regimen, as they have a lower risk of rebleeding 3

Test all patients with bleeding peptic ulcers for H. pylori infection using acute testing followed by confirmatory testing if initial results are negative 3, 4, 1
Provide eradication therapy if positive, as it is an independent predictor of preventing rebleeding in patients with H. pylori infection 3, 4
Restart aspirin as soon as cardiovascular risks outweigh GI risks, usually within 7 days, in patients requiring cardiovascular prophylaxis 1
Aspirin plus PPI therapy is preferred over clopidogrel alone to reduce rebleeding in patients with cardiovascular disease 1
Use a PPI with a cyclooxygenase-2 inhibitor to reduce rebleeding risk in patients requiring ongoing NSAIDs 1

Never rely solely on PPI therapy without endoscopic intervention in active bleeding, as PPIs are adjunctive therapy to endoscopic hemostasis, not a replacement 1, 2
Do not use lower doses in high-risk patients, as only the high-dose continuous infusion has demonstrated mortality benefit 2
Do not discontinue therapy before 6-8 weeks, as premature discontinuation prevents adequate mucosal healing 1, 2
Do not delay restarting antiplatelet therapy in patients requiring cardiovascular prophylaxis beyond 7 days 1

Hospitalize high-risk patients for at least 72 hours after endoscopic hemostasis to monitor for rebleeding and other complications 1
Second-look endoscopy may be useful in selected high-risk patients but is not routinely recommended 1

Empirical administration of an 80 mg IV pantoprazole bolus before endoscopy is based on expert consensus; the supporting evidence is graded C (lower quality) compared with post‑endoscopy use. 5

Four randomized controlled trials and multiple meta‑analyses confirm that the regimen of an 80 mg IV bolus followed immediately by an 8 mg/h continuous infusion significantly reduces rebleeding and the need for surgery in patients with high‑risk endoscopic stigmata (e.g., active arterial bleeding, visible vessel, adherent clot). 6
The recommendation for this high‑dose pantoprazole protocol is supported by Grade A evidence and achieved 100 % consensus among expert panels. 6

All patients presenting with acute upper GI bleeding should undergo rapid H. pylori testing, with a confirmatory test performed if the initial result is negative. 5
When H. pylori infection is confirmed, eradication therapy should be initiated because the infection is an independent predictor of rebleeding. 5
In patients classified as low‑risk for rebleeding (e.g., clean‑based ulcers), oral intake may be resumed within 24 hours after endoscopy. 5

PPI infusion must not delay urgent endoscopy; PPIs serve as adjunctive therapy to endoscopic hemostasis and are not a substitute for timely endoscopic intervention. 5